MEDIGUS LTD - SPON ADR (MDGS)
US58471G4091 - ADR
We assign a fundamental rating of 2 out of 10 to MDGS. MDGS was compared to 196 industry peers in the Health Care Equipment & Supplies industry. MDGS has a bad profitability rating. Also its financial health evaluation is rather negative. MDGS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
MDGS had negative earnings in the past year.
MDGS had a negative operating cash flow in the past year.
MDGS had negative earnings in 4 of the past 5 years.
MDGS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -15.49%, MDGS perfoms like the industry average, outperforming 58.16% of the companies in the same industry.
MDGS's Return On Equity of -41.78% is in line compared to the rest of the industry. MDGS outperforms 51.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.49% | ||
| ROE | -41.78% | ||
| ROIC | N/A |
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 14.92%, MDGS is doing worse than 81.12% of the companies in the same industry.
MDGS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MDGS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
2. Health
2.1 Basic Checks
MDGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDGS has been reduced compared to 1 year ago.
The number of shares outstanding for MDGS has been increased compared to 5 years ago.
MDGS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.19, we must say that MDGS is in the distress zone and has some risk of bankruptcy.
MDGS has a Altman-Z score (-0.19) which is in line with its industry peers.
A Debt/Equity ratio of 0.11 indicates that MDGS is not too dependend on debt financing.
MDGS has a Debt to Equity ratio (0.11) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.19 |
ROIC/WACCN/A
WACC7.66%
2.3 Liquidity
A Current Ratio of 1.30 indicates that MDGS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.30, MDGS is not doing good in the industry: 87.24% of the companies in the same industry are doing better.
MDGS has a Quick Ratio of 1.23. This is a normal value and indicates that MDGS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MDGS (1.23) is worse than 75.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
MDGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -116.00%.
MDGS shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.35%.
The Revenue has been growing by 187.58% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-65%
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Revenue growth Q2Q52.72%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MDGS. In the last year negative earnings were reported.
Also next year MDGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
MDGS has a Yearly Dividend Yield of 29.82%, which is a nice return.
In the last 3 months the price of MDGS has falen by -30.59%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
MDGS's Dividend Yield is rather good when compared to the industry average which is at 2.96. MDGS pays more dividend than 100.00% of the companies in the same industry.
MDGS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 29.82% |
5.2 History
MDGS is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
The earnings of MDGS are negative and hence is the payout ratio. MDGS will probably not be able to sustain this dividend level.
DP-31.57%
EPS Next 2YN/A
EPS Next 3YN/A
MEDIGUS LTD - SPON ADR
NASDAQ:MDGS (4/17/2024, 7:12:04 PM)
After market: 2.6 +0.24 (+10.17%)2.36
+0.18 (+8.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.47M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 29.82% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.49% | ||
| ROE | -41.78% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25.58%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y